A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, everolimus, outcome, trial | 1 Comment »
Data from a randomized clinical trial have shown that there is more than one way to reduce the size of a man’s prostate (if such cytoreduction is needed) prior to treatment with permanent, radioactive pellets (permanent, low-dose brachytherapy) for localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, brachytherapy, cytoreduction, dutasteride, randomized, trial | 6 Comments »
Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: anti-androgen, bicalutamide, castration-resistant, enzalutamide, STRIVE | 1 Comment »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
RTOG 96-01 is a randomized, multi-center Phase III trial designed to compare bicalutamide monotherapy + salvage radiation therapy to a placebo + salvage radiation alone in men with pT2-3N0Mo prostate cancer who have an elevated PSA after surgery. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, outcome, radiation, RTOG 96-01, salvage | 2 Comments »
An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, bicalutamide, effect, orientation, sexual | Leave a comment »
Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH agonist). … READ MORE …
Filed under: Management, Treatment | Tagged: antiandrogen, bicalutamide, high-dose, hormone, second-line, therapy | Leave a comment »
A number of physicians and patients have believed for years that so-called “triple” androgen blockade (ADT3) is a more effective option than an LHRH alone or combined androgen deprivation in the treatment of men with advanced prostate cancer. However, the clinical evidence supporting this belief has been limited. … READ MORE …
Filed under: Management, Treatment | Tagged: ADT3, bicalutamide, dutasteride, TARP | 4 Comments »
In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, monotherapy, pprophylaxis, tamoxifen | 1 Comment »
According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, Casodex, generic | Comments Off on Generic bicalutamide now available in the USA
In today’s news reports we address such issues as:
Filed under: Management, Prevention, Treatment, Uncategorized | Tagged: bicalutamide, mortality, outcome, racial disparities, weekly | Leave a comment »
The reports addressed today offer information from three very technical studies dealing with:
Filed under: Diagnosis, Drugs in development, Prevention, Risk | Tagged: African American, bicalutamide, DNA licensing, genomic profile, interleukin-6 | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 